Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage - a Multi-center Randomized Double-blind Clinical Trial

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Patients with subarachnoid hemorrhage are prone to suffer from dysnatriemia. Evidence shows that hyponatriemia is associated with increased incidence of vasospasm, brain swelling and mortality in these patients. Patients with subarachnoid hemorrhage often require large amounts of iv fluids in order to maintain euvolemia and support cardiocirculatory function. Prior evidence shows that the type of infusion fluid significantly influences blood sodium content. Hence, this study evaluated whether the sodium content of the infusion solution impacts mortality and morbidity in patients with subarachnoid hemorrhage.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 16
Healthy Volunteers: f
View:

• All adult patients suffering from non-traumatic subarachnoid haemorrhage.

Locations
Other Locations
Switzerland
Department of Intensive Care, Bern University Hospital and University of Bern, Bern, Switzerland
RECRUITING
Bern
Department of Intensive Care Medicine
RECRUITING
Geneva
Department of perioperative Intensive Care Medicine
RECRUITING
Sankt Gallen
Contact Information
Primary
Anna S Messmer, MD
anna.messmer@insel.ch
+41316322111
Backup
Research Nurses Department of Intensive Care
kim.researchnurses@insel.ch
+41316322111
Time Frame
Start Date: 2022-05-24
Estimated Completion Date: 2026-07
Participants
Target number of participants: 320
Treatments
Active_comparator: high sodium infusion fluid
Patients will exclusively receive 0.9% saline (sodium content 154mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
Active_comparator: low sodium infusion fluid
Patients will exclusively receive lactated Ringer's (sodium content 130mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
Related Therapeutic Areas
Sponsors
Leads: Insel Gruppe AG, University Hospital Bern

This content was sourced from clinicaltrials.gov